Cholesterol treatment injection
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Cholesterol Treatment Injections: Efficacy and Safety
Inclisiran: A Promising Biannual Injection for Hypercholesterolemia
Inclisiran, a small interfering RNA, has emerged as a significant advancement in the treatment of hypercholesterolemia, particularly for patients who do not achieve target low-density lipoprotein (LDL) levels with statins or cannot tolerate them. Inclisiran works by inhibiting the hepatic synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9), leading to substantial reductions in LDL cholesterol levels. Clinical trials have demonstrated that inclisiran, administered biannually, can decrease LDL cholesterol by approximately 51% compared to placebo, with a significant reduction in major adverse cardiovascular events by 24% .
Alirocumab: Biweekly Injections for LDL Reduction
Alirocumab, a monoclonal antibody targeting PCSK9, has shown efficacy in reducing LDL cholesterol levels in patients on maximum tolerated doses of statins. Administered biweekly, alirocumab has been associated with a 62% reduction in LDL cholesterol levels at 24 weeks, with sustained effects over 78 weeks. Additionally, a post hoc analysis indicated a reduction in major adverse cardiovascular events. However, higher rates of injection-site reactions, myalgia, and neurocognitive events were noted compared to placebo.
Danhong Injection (DHI): Traditional Chinese Medicine for Dyslipidemia
Danhong injection (DHI), used in traditional Chinese medicine, has shown potential in treating dyslipidemia. In high-fat diet-fed rats, DHI significantly reduced total cholesterol, triglycerides, and LDL cholesterol levels while increasing high-density lipoprotein (HDL) cholesterol. The treatment also improved liver function and reduced oxidative stress, suggesting its potential as a hypolipidemic agent.
Patient Acceptance of Subcutaneous Injections
The acceptance of subcutaneous injections for cholesterol treatment is crucial for patient compliance. The Injection-Treatment Acceptance Questionnaire (I-TAQ) was developed to assess patient perspectives on such treatments. Initial findings indicate that while some patients initially fear needles, this fear generally subsides without impacting adherence. Key factors influencing acceptance include perceived efficacy, side effects, and convenience.
Conclusion
Cholesterol treatment injections, particularly inclisiran and alirocumab, offer significant benefits in reducing LDL cholesterol levels and associated cardiovascular risks. Inclisiran's biannual dosing regimen may improve patient compliance compared to more frequent injections required for alirocumab. Traditional treatments like Danhong injection also show promise in managing dyslipidemia. Understanding patient acceptance of these treatments is essential for optimizing adherence and achieving desired health outcomes.
Sources and full results
Most relevant research papers on this topic